Cell & Gene Therapy Manufacturing Services Market Projected to Reach USD 38.9 Billion by 2031

The Cell & Gene Therapy Manufacturing Services Market size was estimated at USD 6.1 billion in 2023. It is expected to reach USD 38.9 billion by 2031, growing at a compound annual growth rate (CAGR) of 22.3% during the forecast period from 2023 to 2030.

Cell and gene therapies are innovative medical treatments that involve the modification of a patient's cells or genes to treat or prevent diseases. The manufacturing of these therapies is a complex and highly regulated process that requires specialized facilities, equipment, and expertise. The increasing demand for cell and gene therapies, coupled with the growing number of clinical trials and commercialized products, is driving the expansion of the cell and gene therapy manufacturing services market.

The market growth is further propelled by the advancements in manufacturing technologies, such as the development of scalable and automated production systems, the adoption of single-use technologies, and the integration of digital solutions for process monitoring and control. The collaborations between pharmaceutical companies, contract manufacturing organizations (CMOs), and academic institutions are also contributing to the market's growth by enhancing the manufacturing capabilities and accelerating the development of novel therapies.

Download Free Sample Report of Cell & Gene Therapy Manufacturing Services Market @ https://www.snsinsider.com/sample-request/1187

List of Cell & Gene Therapy Manufacturing Services Market Companies Profiled in Report:
- Bluebird Bio Inc.
- Boehringer Ingelheim
- Catalent Inc.
- Cellular Therapeutics
- F. Hoffmann-La Roche Ltd.
- Hitachi Chemical Co., Ltd.
- Lonza
- Merck KGaA
- Miltenyi Biotec
- Novartis AG
- Samsung Biologics
- Takara Bio Inc.
- Thermo Fisher Scientific
- Wuxi Advanced Therapies

Market Analysis
The rising prevalence of genetic disorders and cancer, along with the increasing investments in research and development activities for cell and gene therapies, are key drivers for the market. The growing demand for personalized medicine and the favorable regulatory environment, with initiatives to streamline the approval process for advanced therapies, are also fueling the market growth. Additionally, the increasing outsourcing of manufacturing activities by pharmaceutical and biotechnology companies to specialized CMOs is creating new opportunities for market players.

Recent Developments in the Cell & Gene Therapy Manufacturing Services Market
In July 2024, Lonza Group AG announced the expansion of its cell and gene therapy manufacturing facility in Houston, Texas. This expansion will double Lonza's production capacity for viral vectors and enable the company to meet the growing demand for gene therapy manufacturing services. The expanded facility will feature state-of-the-art manufacturing suites, automated systems, and digital solutions to ensure efficient and scalable production of gene therapies. This investment underscores Lonza's commitment to supporting the development and commercialization of advanced therapies and strengthens its position as a leading CMO in the cell and gene therapy market.

In April 2024, Thermo Fisher Scientific Inc. launched its new Cell Therapy Systems (CTS) Series, a range of scalable and automated manufacturing solutions for cell therapy production. The CTS Series includes closed-system cell processing equipment, modular cleanroom facilities, and integrated software solutions for process control and data management. These innovative solutions aim to streamline the manufacturing workflow, reduce contamination risks, and improve the consistency and quality of cell therapy products. The launch of the CTS Series highlights Thermo Fisher's efforts to provide comprehensive solutions for cell therapy manufacturing and support the growing demand for advanced therapies.

Key Market Segmentation
By Type
➤ Cell Therapy
➔ Allogeneic
◘ Mesenchymal Stem Cells
◘ T-cells
◘ Induced Pluripotent Stem Cells
◘ Natural Killer Cells
◘ Hematopoietic Stem Cells
◘ Other Allogeneic Cells
➔ Autologous
◘ T-cells
◘ Hematopoietic Stem Cells
◘ Mesenchymal Stem Cells
◘ Natural Killer Cells
◘ Other Autologous Cells
➔ Viral Vector
◘ Retroviral Vectors
◘ Adeno-associated Virus Vectors
◘ Other Viral Vectors
➤ Gene Therapy
➔ Viral Vector
◘ Retroviral Vectors
◘ Adeno-associated Virus Vectors
◘ Other Viral Vectors
➔ Non-viral Vector
◘ Oligonucleotides
◘ Other Non-viral Vectors

By Indication
➤ Oncology Diseases
➤ Cardiovascular Diseases
➤ Orthopedic Diseases
➤ Ophthalmology Diseases
➤ Central Nervous System Disorders
➤ Infectious Diseases
➤ Other Indications

By Application
➤ Clinical Manufacturing
➤ Commercial Manufacturing

Have Any Query? Ask Our Experts @ https://www.snsinsider.com/enquiry/1187

Impact of Russia-Ukraine War on the Cell & Gene Therapy Manufacturing Services Market
The ongoing Russia-Ukraine war is likely to have a limited direct impact on the cell and gene therapy manufacturing services market, as neither country is a major player in this industry. However, the war may indirectly affect the market through disruptions in the supply chain of raw materials, reagents, and equipment, potentially leading to temporary shortages and price fluctuations.

Impact of Economic Slowdown on the Cell & Gene Therapy Manufacturing Services Market
An economic slowdown could potentially affect the cell and gene therapy manufacturing services market, particularly in terms of investments in research and development activities and the funding of clinical trials. However, the impact is expected to be moderate, as the demand for advanced therapies is driven by the high unmet medical needs in various disease areas, and the long-term growth prospects of the market remain positive. Moreover, the increasing collaborations between pharmaceutical companies and CMOs may help mitigate the impact of economic slowdowns by sharing the financial risks and leveraging the expertise of specialized manufacturing partners.

North America Is Expected To Hold The Largest Market Share Throughout The Forecast Period
This dominance can be attributed to factors such as the presence of well-established CMOs, the high number of ongoing clinical trials for cell and gene therapies, and the favorable regulatory environment in the region. The United States is a key contributor to the market, with a robust pipeline of advanced therapies and significant investments in manufacturing infrastructure. Europe is also expected to hold a significant share, driven by the increasing adoption of cell and gene therapies, the growing number of collaborations between pharmaceutical companies and CMOs, and the supportive initiatives by regulatory authorities to accelerate the development of advanced therapies.

Key Takeaways for Market Report Purchasers
- A comprehensive analysis of the cell and gene therapy manufacturing services market, encompassing current trends, growth drivers, and challenges.
- Insightful segmentation of the market by Therapy Type, Scale, and Geography, providing a thorough understanding of each segment's dynamics.
- Evaluation of the impact of the Russia-Ukraine war and economic slowdown on the market's growth trajectory.
- In-depth examination of key regional developments and the factors influencing market dominance.

Purchase Cell & Gene Therapy Manufacturing Services Market Report @ https://www.snsinsider.com/checkout/1187

Table of Content
Chapter 1 Introduction
Chapter 2 Research Methodology
Chapter 3 Cell & Gene Therapy Manufacturing Services Market Dynamics
Chapter 4 Impact Analysis (COVID-19, Ukraine- Russia war, Ongoing Recession on Major Economies)
Chapter 5 Value Chain Analysis
Chapter 6 Porter's 5 forces model
Chapter 7 PEST Analysis
Chapter 8 Cell & Gene Therapy Manufacturing Services Market Segmentation, By Type
Chapter 9 Cell & Gene Therapy Manufacturing Services Market Segmentation, By Indication
Chapter 10 Cell & Gene Therapy Manufacturing Services Market Segmentation, By Application
Chapter 11 Regional Analysis
Chapter 12 Company profile
Chapter 13 Competitive Landscape
Chapter 14 Use Case and Best Practices
Chapter 15 Conclusion
Continued…

Other Reports
Telehealth and Telemedicine Market: https://whatech.com/og/markets-research/medical/836751-telehealth-and-telemedicine-market-size-share-analysis-and-to-surpass-usd-818-87-billion-by-2031

Healthcare IT Integration Market: https://whatech.com/og/markets-research/medical/836756-healthcare-it-integration-market-size-trends-growth-and-forecasted-to-reach-usd-12-40-billion-by-2031

Contact Us:
Akash Anand - Head of Business Development & Strategy
info@snsinsider.com
Phone: +1-415-230-0044 | +91-7798602273 (IND)

About US:
SNS Insider has been a leader in data and analytics globally with its authentic consumer and market insights. The trust of our clients and business partners has always been at the center of who we are as a company. We are a business that leads the industry in innovation, and to support the success of our clients, our highly skilled engineers, consultants, and data scientists have consistently pushed the limits of the industry with innovative methodology and measuring technologies.

This release was published on openPR.